Contact this trialFirst, we need to learn more about you.
Lenvatinib + TACE for Liver Cancer
Recruiting3 awardsPhase 2
Houston, Texas
This trial will study if adding the drug lenvatinib to transcatheter arterial chemoembolization (TACE) before liver transplantation will improve outcomes in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service